NEW YORK (GenomeWeb) – Epigenomics today announced that the US Food and Drug Administration has requested further data before making a decision on whether to approve the firm's blood-based colorectal cancer screening test.

Epigenomics has received a response letter from the FDA providing guidance and recommendations for improving the pre-market approval application for the German molecular diagnostics firm's Epi proColon screening test. The FDA requested additional data showing that the test will increase compliance to colorectal cancer screening in the intended use population.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.